TY - JOUR AU - Ayyar, B. V. AU - Arora, S. AU - O’Kennedy, R. PY - 2016 DA - 2016// TI - Coming-of-age of antibodies in cancer therapeutics JO - Trends Pharmacol Sci VL - 37 UR - https://doi.org/10.1016/j.tips.2016.09.005 DO - 10.1016/j.tips.2016.09.005 ID - Ayyar2016 ER - TY - JOUR AU - Smith-Jones, P. M. AU - Solit, D. AU - Afroze, F. AU - Rosen, N. AU - Larson, S. M. PY - 2006 DA - 2006// TI - Early tumor response to Hsp90 therapy using HER2 PET: comparison with F-18-FDG PET JO - J Nucl Med VL - 47 ID - Smith-Jones2006 ER - TY - JOUR AU - Smith-Jones, P. M. AU - Solit, D. B. AU - Akhurst, T. AU - Afroze, F. AU - Rosen, N. AU - Larson, S. M. PY - 2004 DA - 2004// TI - Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors JO - Nat Biotechnol VL - 22 UR - https://doi.org/10.1038/nbt968 DO - 10.1038/nbt968 ID - Smith-Jones2004 ER - TY - JOUR AU - Gebhart, G. AU - Lamberts, L. E. AU - Wimana, Z. AU - Garcia, C. AU - Emonts, P. AU - Ameye, L. PY - 2016 DA - 2016// TI - Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdv577 DO - 10.1093/annonc/mdv577 ID - Gebhart2016 ER - TY - JOUR AU - Carrasquillo, J. A. AU - Pandit-Taskar, N. AU - O'Donoghue, J. A. AU - Humm, J. L. AU - Zanzonico, P. AU - Smith-Jones, P. M. PY - 2011 DA - 2011// TI - (124)I-huA33 antibody PET of colorectal cancer JO - J Nucl Med VL - 52 UR - https://doi.org/10.2967/jnumed.110.086165 DO - 10.2967/jnumed.110.086165 ID - Carrasquillo2011 ER - TY - JOUR AU - Divgi, C. R. AU - Uzzo, R. G. AU - Gatsonis, C. AU - Bartz, R. AU - Treutner, S. AU - Yu, J. Q. PY - 2013 DA - 2013// TI - Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2011.41.2445 DO - 10.1200/JCO.2011.41.2445 ID - Divgi2013 ER - TY - JOUR AU - Arbit, E. AU - Cheung, N. K. V. AU - Yeh, S. D. J. AU - Daghighian, F. AU - Zhang, J. J. AU - Cordoncardo, C. PY - 1995 DA - 1995// TI - Quantitative studies of monoclonal-antibody targeting to disialoganglioside G(D2) in human brain tumors JO - Eur J Nucl Med VL - 22 UR - https://doi.org/10.1007/BF00839056 DO - 10.1007/BF00839056 ID - Arbit1995 ER - TY - JOUR AU - O’Donoghue, J. A. AU - Smith-Jones, P. M. AU - Humm, J. L. AU - Ruan, S. T. AU - Pryma, D. A. AU - Jungbluth, A. A. PY - 2011 DA - 2011// TI - I-124-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET JO - J Nucl Med VL - 52 UR - https://doi.org/10.2967/jnumed.111.095596 DO - 10.2967/jnumed.111.095596 ID - O’Donoghue2011 ER - TY - JOUR AU - Zanzonico, P. AU - Carrasquillo, J. A. AU - Pandit-Taskar, N. AU - O’Donoghue, J. A. AU - Humm, J. L. AU - Smith-Jones, P. PY - 2015 DA - 2015// TI - PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer JO - Eur J Nucl Med Mol Imaging VL - 42 UR - https://doi.org/10.1007/s00259-015-3061-2 DO - 10.1007/s00259-015-3061-2 ID - Zanzonico2015 ER - TY - JOUR AU - Beylergil, V. AU - Morris, P. G. AU - Smith-Jones, P. M. AU - Modi, S. AU - Solit, D. AU - Hudis, C. A. PY - 2013 DA - 2013// TI - Pilot study of Ga-68-DOTA-F(ab′)(2)-trastuzumab in patients with breast cancer JO - Nucl Med Commun VL - 34 ID - Beylergil2013 ER - TY - STD TI - Carrasquillo JA, Morris PG, Humm JL, Smith-Jones PM, Beylergil V, Akhurst T, et al. Copper-64 trastuzumab PET imaging: a reproducibility study. Q J Nucl Med Mol Imaging. 2016; [Epub ahead of print] ID - ref11 ER - TY - JOUR AU - Dijkers, E. C. AU - Munnink, T. H. O. AU - Kosterink, J. G. AU - Brouwers, A. H. AU - Jager, P. L. AU - de Jong, J. R. PY - 2010 DA - 2010// TI - Biodistribution of Zr-89-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer JO - Clin Pharmacol Ther VL - 87 UR - https://doi.org/10.1038/clpt.2010.12 DO - 10.1038/clpt.2010.12 ID - Dijkers2010 ER - TY - JOUR AU - Pandit-Taskar, N. AU - O’Donoghue, J. A. AU - Beylergil, V. AU - Lyashchenko, S. AU - Ruan, S. T. AU - Solomon, S. B. PY - 2014 DA - 2014// TI - Zr-89-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer JO - Eur J Nucl Med Mol Imaging VL - 41 UR - https://doi.org/10.1007/s00259-014-2830-7 DO - 10.1007/s00259-014-2830-7 ID - Pandit-Taskar2014 ER - TY - JOUR AU - Osborne, J. R. AU - Green, D. A. AU - Spratt, D. E. AU - Lyashchenko, S. AU - Fareedy, S. B. AU - Robinson, B. D. PY - 2014 DA - 2014// TI - A prospective pilot study of Zr-89-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy JO - J Urol VL - 191 UR - https://doi.org/10.1016/j.juro.2013.10.041 DO - 10.1016/j.juro.2013.10.041 ID - Osborne2014 ER - TY - JOUR AU - Pandit-Taskar, N. AU - O’Donoghue, J. A. AU - Ruan, S. T. AU - Lyashchenko, S. K. AU - Carrasquillo, J. A. AU - Heller, G. PY - 2016 DA - 2016// TI - First-in-human imaging with Zr-89-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake JO - J Nucl Med VL - 57 UR - https://doi.org/10.2967/jnumed.116.176206 DO - 10.2967/jnumed.116.176206 ID - Pandit-Taskar2016 ER - TY - JOUR AU - Ulaner, G. A. AU - Hyman, D. M. AU - Ross, D. S. AU - Corben, A. AU - Chandarlapaty, S. AU - Goldfarb, S. PY - 2016 DA - 2016// TI - Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT JO - J Nucl Med VL - 57 UR - https://doi.org/10.2967/jnumed.115.172031 DO - 10.2967/jnumed.115.172031 ID - Ulaner2016 ER - TY - JOUR AU - Hanaoka, H. AU - Nagaya, T. AU - Sato, K. AU - Nakamura, Y. AU - Watanabe, R. AU - Harada, T. PY - 2015 DA - 2015// TI - Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy JO - Mol Pharm VL - 12 UR - https://doi.org/10.1021/acs.molpharmaceut.5b00132 DO - 10.1021/acs.molpharmaceut.5b00132 ID - Hanaoka2015 ER - TY - JOUR AU - Yang, X. AU - Liu, H. AU - Sun, C. K. AU - Natarajan, A. AU - Hu, X. AU - Wang, X. PY - 2014 DA - 2014// TI - Imaging of hepatocellular carcinoma patient-derived xenografts using Zr-89-labeled anti-glypican-3 monoclonal antibody JO - Biomaterials VL - 35 UR - https://doi.org/10.1016/j.biomaterials.2014.04.089 DO - 10.1016/j.biomaterials.2014.04.089 ID - Yang2014 ER - TY - JOUR AU - Filmus, J. AU - Selleck, S. B. PY - 2001 DA - 2001// TI - Glypicans: proteoglycans with a surprise JO - J Clin Invest VL - 108 UR - https://doi.org/10.1172/JCI200113712 DO - 10.1172/JCI200113712 ID - Filmus2001 ER - TY - JOUR AU - Feng, M. Q. AU - Ho, M. PY - 2014 DA - 2014// TI - Glypican-3 antibodies: a new therapeutic target for liver cancer JO - FEBS Lett VL - 588 UR - https://doi.org/10.1016/j.febslet.2013.10.002 DO - 10.1016/j.febslet.2013.10.002 ID - Feng2014 ER - TY - JOUR AU - Capurro, M. AU - Wanless, I. R. AU - Sherman, M. AU - Deboer, G. AU - Shi, W. AU - Miyoshi, E. PY - 2003 DA - 2003// TI - Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma JO - Gastroenterology VL - 125 UR - https://doi.org/10.1016/S0016-5085(03)00689-9 DO - 10.1016/S0016-5085(03)00689-9 ID - Capurro2003 ER - TY - JOUR AU - Zhu, A. X. AU - Gold, P. J. AU - El-Khoueiry, A. B. AU - Abrams, T. A. AU - Morikawa, H. AU - Ohishi, N. PY - 2013 DA - 2013// TI - First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2616 DO - 10.1158/1078-0432.CCR-12-2616 ID - Zhu2013 ER - TY - JOUR AU - Yorita, K. AU - Takahashi, N. AU - Takai, H. AU - Kato, A. AU - Suzuki, M. AU - Ishiguro, T. PY - 2011 DA - 2011// TI - Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma JO - Liver Int VL - 31 UR - https://doi.org/10.1111/j.1478-3231.2010.02359.x DO - 10.1111/j.1478-3231.2010.02359.x ID - Yorita2011 ER - TY - JOUR AU - Nakano, K. AU - Ishiguro, T. AU - Konishi, H. AU - Tanaka, M. AU - Sugimoto, M. AU - Sugo, I. PY - 2010 DA - 2010// TI - Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization JO - Anti-Cancer Drugs VL - 21 UR - https://doi.org/10.1097/CAD.0b013e32833f5d68 DO - 10.1097/CAD.0b013e32833f5d68 ID - Nakano2010 ER - TY - JOUR AU - Ishiguro, T. AU - Sugimoto, M. AU - Kinoshita, Y. AU - Miyazaki, Y. AU - Nakano, K. AU - Tsunoda, H. PY - 2008 DA - 2008// TI - Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-1973 DO - 10.1158/0008-5472.CAN-08-1973 ID - Ishiguro2008 ER - TY - JOUR AU - Ikeda, M. AU - Ohkawa, S. AU - Okusaka, T. AU - Mitsunaga, S. AU - Kobayashi, S. AU - Morizane, C. PY - 2014 DA - 2014// TI - Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma JO - Cancer Sci VL - 105 UR - https://doi.org/10.1111/cas.12368 DO - 10.1111/cas.12368 ID - Ikeda2014 ER - TY - JOUR AU - Abou-Alfa, G. K. AU - Yen, C. J. AU - Hsu, C. H. AU - O’Donoghue, J. AU - Beylergil, V. AU - Ruan, S. T. PY - 2017 DA - 2017// TI - Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) JO - Cancer Chemother Pharmacol VL - 79 UR - https://doi.org/10.1007/s00280-017-3241-9 DO - 10.1007/s00280-017-3241-9 ID - Abou-Alfa2017 ER - TY - CHAP AU - Finn, R. AU - Balatoni, J. AU - Kothari, P. AU - Pentlow, K. AU - Sheh, Y. AU - Lom, C. ED - Duggan, J. L. ED - Morgan, I. L. PY - 2001 DA - 2001// TI - Cyclotron production and potential clinical application of iodine-124 labeled radiotracers BT - Application of accelerators in research and industry ID - Finn2001 ER - TY - JOUR AU - Lindmo, T. AU - Boven, E. AU - Cuttitta, F. AU - Fedorko, J. AU - Bunn, P. A. PY - 1984 DA - 1984// TI - Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess JO - J Immunol Methods VL - 72 UR - https://doi.org/10.1016/0022-1759(84)90435-6 DO - 10.1016/0022-1759(84)90435-6 ID - Lindmo1984 ER - TY - JOUR AU - Stabin, M. G. AU - Sparks, R. B. AU - Crowe, E. PY - 2005 DA - 2005// TI - OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine JO - J Nucl Med VL - 46 ID - Stabin2005 ER - TY - JOUR AU - Barrett, P. H. R. AU - Bell, B. M. AU - Cobelli, C. AU - Golde, H. AU - Schumitzky, A. AU - Vicini, P. PY - 1998 DA - 1998// TI - SAAM II: stimulation, analysis, and modeling software for tracer and pharmacokinetic studies JO - Metabolism VL - 47 UR - https://doi.org/10.1016/S0026-0495(98)90064-6 DO - 10.1016/S0026-0495(98)90064-6 ID - Barrett1998 ER - TY - JOUR AU - Retzlaff, J. A. AU - Tauxe, W. N. AU - Kiely, J. M. AU - Stroebel, C. F. PY - 1969 DA - 1969// TI - Erythrocyte volume, plasma volume, and lean body mass in adult men and women JO - Blood VL - 33 ID - Retzlaff1969 ER - TY - JOUR AU - KS, M. C. AU - Szabo, E. AU - Flowers, J. L. AU - Cox, E. B. AU - Leight, G. S. AU - Miller, L. PY - 1986 DA - 1986// TI - Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors JO - Cancer Res VL - 46 ID - KS1986 ER - TY - JOUR AU - Haruyama, Y. AU - Yorita, K. AU - Yamaguchi, T. AU - Kitajima, S. AU - Amano, J. AU - Ohtomo, T. PY - 2015 DA - 2015// TI - High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy JO - Int J Cancer VL - 137 UR - https://doi.org/10.1002/ijc.29518 DO - 10.1002/ijc.29518 ID - Haruyama2015 ER - TY - JOUR AU - Naruki, Y. AU - Carrasquillo, J. A. AU - Reynolds, J. C. AU - Maloney, P. J. AU - Frincke, J. M. AU - Neumann, R. D. PY - 1990 DA - 1990// TI - Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody JO - Int J Rad Appl Instrum B VL - 17 UR - https://doi.org/10.1016/0883-2897(90)90148-T DO - 10.1016/0883-2897(90)90148-T ID - Naruki1990 ER - TY - JOUR AU - Yao, Z. S. AU - Garmestani, K. AU - Wong, K. J. AU - Park, L. S. AU - Dadachova, E. AU - Yordanov, A. PY - 2001 DA - 2001// TI - Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody JO - J Nucl Med VL - 42 ID - Yao2001 ER - TY - JOUR AU - Cheal, S. M. AU - Punzalan, B. AU - Doran, M. G. AU - Evans, M. J. AU - Osborne, J. R. AU - Lewis, J. S. PY - 2014 DA - 2014// TI - Pairwise comparison of (89)Zr- and (124)I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma JO - Eur J Nucl Med Mol Imaging VL - 41 UR - https://doi.org/10.1007/s00259-013-2679-1 DO - 10.1007/s00259-013-2679-1 ID - Cheal2014 ER - TY - JOUR AU - Divgi, C. R. AU - O’Donoghue, J. A. AU - Welt, S. AU - O’Neel, J. AU - Finn, R. AU - Motzer, R. J. PY - 2004 DA - 2004// TI - Phase I clinical trial with fractionated radioimmunotherapy using I-13-labeled chimeric G250 in metastatic renal cancer JO - J Nucl Med VL - 45 ID - Divgi2004 ER -